Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Completed · Phase 2

Conditions studied: Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma

In brief

This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).

Key facts

Study ID

NCT01980654

Run by

Pharmacyclics LLC.

People needed

80

Starts

2013-12-01

Expected to finish

2017-11-01

Last updated by the study team

2019-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Providence Saint Joseph Medical Center — Burbank, California, United States
• City of Hope — Duarte, California, United States
• UCLA Medical Center — Los Angeles, California, United States
• Stanford University, Stanford Care Center — Stanford, California, United States
• Southeastern Regional Medical Center — Newnan, Georgia, United States
• Community Health Network Community Regional Cancer Center North — Indianapolis, Indiana, United States
• Comprehensive Cancer Centers of Nevada — Henderson, Nevada, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Weill Cornell Medical College New York-Presbyterian Hospital — New York, New York, United States
• Mid-Ohio Oncology/ Hematology Inc — Columbus, Ohio, United States
• Tennessee Oncology, PLLC The Sarah Cannon Research Institute — Nashville, Tennessee, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.